Daniel Paris

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11815789/publications.pdf

Version: 2024-02-01

74 papers	3,497 citations	126907 33 h-index	144013 57 g-index
76 all docs	76 docs citations	76 times ranked	4763 citing authors

#	Article	IF	Citations
1	Microglial Activation Resulting from CD40-CD40L Interaction After -Amyloid Stimulation. Science, 1999, 286, 2352-2355.	12.6	340
2	Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. Journal of Neuroinflammation, 2005, 2, 9.	7.2	262
3	Reduction of Î²-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. Journal of Neuroinflammation, 2010, 7, 17.	7.2	148
4	Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neuroscience Letters, 2004, 366, 80-85.	2.1	121
5	Inhibition of Angiogenesis by AÂ Peptides. Angiogenesis, 2004, 7, 75-85.	7.2	119
6	Î±-Sheet secondary structure in amyloid Î²-peptide drives aggregation and toxicity in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8895-8900.	7.1	118
7	Vasoactive effects of AÎ²in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: Role of inflammation. Neurological Research, 2003, 25, 642-651.	1.3	112
8	Lifelong behavioral and neuropathological consequences of repetitive mild traumatic brain injury. Annals of Clinical and Translational Neurology, 2018, 5, 64-80.	3.7	110
9	Selective Antihypertensive Dihydropyridines Lower AÎ² Accumulation by Targeting both the Production and the Clearance of AÎ² across the Blood-Brain Barrier. Molecular Medicine, 2011, 17, 149-162.	4.4	104
10	Inhibition of angiogenesis and tumor growth by Î² and Î³-secretase inhibitors. European Journal of Pharmacology, 2005, 514, 1-15.	3.5	86
11	Alzheimerâ€™s Î²â€amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFRâ€2. Journal of Neurochemistry, 2010, 112, 66-76.	3.9	84
12	The Spleen Tyrosine Kinase (Syk) Regulates Alzheimer Amyloid-Î² Production and Tau Hyperphosphorylation. Journal of Biological Chemistry, 2014, 289, 33927-33944.	3.4	84
13	Inhibition of AÎ² production by NF-ÎºB inhibitors. Neuroscience Letters, 2007, 415, 11-16.	2.1	79
14	Nilvadipine antagonizes both AÎ² vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Research, 2004, 999, 53-61.	2.2	77
15	Activation of microglial cells by the CD40 pathway: relevance to multiple sclerosis. Journal of Neuroimmunology, 1999, 97, 77-85.	2.3	73
16	Inhibition of Alzheimer's Î²-Amyloid Induced Vasoactivity and Proinflammatory Response in Microglia by a cGMP-Dependent Mechanism. Experimental Neurology, 1999, 157, 211-221.	4.1	68
17	Soluble Î²-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiology of Aging, 2000, 21, 183-197.	3.1	61
18	Selective dihydropyiridine compounds facilitate the clearance of Î²-amyloid across the bloodâ€“brain barrier. European Journal of Pharmacology, 2011, 659, 124-129.	3.5	61

#	Article	IF	Citations
19	Distinct Signaling Pathways Regulate TREM2 Phagocytic and NFÎºB Antagonistic Activities. Frontiers in Cellular Neuroscience, 2019, 13, 457.	3.7	61
20	Anatabine lowers Alzheimer's AÎ² production in vitro and in vivo. European Journal of Pharmacology, 2011, 670, 384-391.	3.5	51
21	Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation. European Journal of Pharmacology, 2013, 698, 145-153.	3.5	45
22	A Multifaceted Role for apoE in the Clearance of Beta-Amyloid across the Blood-Brain Barrier. Neurodegenerative Diseases, 2013, 11, 13-21.	1.4	42
23	Novel strategies for opposing murine microglial activation. Neuroscience Letters, 2000, 278, 5-8.	2.1	41
24	Pro-inflammatory effect of freshly solubilized Î²-amyloid peptides in the brain. Prostaglandins and Other Lipid Mediators, 2002, 70, 1-12.	1.9	41
25	Apolipoprotein E Isoform-Specific Effects on Lipoprotein Receptor Processing. NeuroMolecular Medicine, 2014, 16, 686-696.	3.4	41
26	Isoform-specific vasoconstriction induced by Apolipoprotein E and modulation of this effect by Alzheimer's Î²-amyloid peptide. Neuroscience Letters, 1998, 256, 73-76.	2.1	39
27	Role of the cannabinoid system in the transit of beta-amyloid across the bloodâ€“brain barrier. Molecular and Cellular Neurosciences, 2013, 56, 255-262.	2.2	39
28	Flavonoids lower Alzheimer's AÃŸ production via an NFkB dependent mechanism. Bioinformation, 2011, 6, 229-236.	0.5	39
29	Stimulation of the Retinoid X Receptor Facilitates Beta-Amyloid Clearance Across the Bloodâ€“Brain Barrier. Journal of Molecular Neuroscience, 2013, 49, 270-276.	2.3	38
30	Diagnostic utility of APOE, soluble CD40, CD40L, and AÎ²1â€“40 levels in plasma in Alzheimerâ€™s disease. Cytokine, 2008, 44, 283-287.	3.2	37
31	Alzheimerâ€™s disease pathological lesions activate the spleen tyrosine kinase. Acta Neuropathologica Communications, 2017, 5, 69.	5.2	36
32	Oleoylethanolamide treatment reduces neurobehavioral deficits and brain pathology in a mouse model of Gulf War Illness. Scientific Reports, 2018, 8, 12921.	3.3	36
33	Amelioration of Experimental Autoimmune Encephalomyelitis by Anatabine. PLoS ONE, 2013, 8, e55392.	2.5	36
34	The influence of diagnosis, intra- and inter-person variability on serum and plasma AÎ² levels. Neuroscience Letters, 2007, 428, 53-58.	2.1	34
35	Role of Peroxynitrite in the Vasoactive and Cytotoxic Effects of Alzheimer's Î²-Amyloid1â€“40Peptide. Experimental Neurology, 1998, 152, 116-122.	4.1	33
36	Statins inhibit AÎ²-neurotoxicity in vitro and AÎ²-induced vasoconstriction and inflammation in rat aortae. Atherosclerosis, 2002, 161, 293-299.	0.8	32

#	Article	IF	Citations
37	Anti-angiogenic activity of the mutant Dutch AÎ² peptide on human brain microvascular endothelial cells. Molecular Brain Research, 2005, 136, 212-230.	2.3	31
38	Spleen tyrosine kinase (SYK) blocks autophagic Tau degradation in vitro and in vivo. Journal of Biological Chemistry, 2019, 294, 13378-13395.	3.4	31
39	A permethrin metabolite is associated with adaptive immune responses in Gulf War Illness. Brain, Behavior, and Immunity, 2019, 81, 545-559.	4.1	31
40	Genomic regulation after CD40 stimulation in microglia: Relevance to Alzheimer's disease. Molecular Brain Research, 2005, 140, 73-85.	2.3	30
41	Characterization and use of human brain microvascular endothelial cells to examine Î²-amyloid exchange in the blood-brain barrier. Cytotechnology, 2010, 62, 519-529.	1.6	30
42	Abeta Vasoactivity: An Inflammatory Reaction. Annals of the New York Academy of Sciences, 2000, 903, 97-109.	3.8	29
43	Acute or Delayed Treatment with Anatabine Improves Spatial Memory and Reduces Pathological Sequelae at Late Time-Points after Repetitive Mild Traumatic Brain Injury. Journal of Neurotrauma, 2017, 34, 1676-1691.	3.4	29
44	Chronic Anatabine Treatment Reduces Alzheimerâ€™s Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD. PLoS ONE, 2015, 10, e0128224.	2.5	26
45	Impaired Orthotopic Glioma Growth and Vascularization in Transgenic Mouse Models of Alzheimer's Disease. Journal of Neuroscience, 2010, 30, 11251-11258.	3.6	25
46	MMP9 modulation improves specific neurobehavioral deficits in a mouse model of Alzheimerâ€™s disease. BMC Neuroscience, 2021, 22, 39.	1.9	25
47	beta-Amyloid Vasoactivity and Proinflammation in Microglia Can Be Blocked by cGMP-Elevating Agents. Annals of the New York Academy of Sciences, 2000, 903, 446-450.	3.8	24
48	Targeting sirtuin activity with nicotinamide riboside reduces neuroinflammation in a GWI mouse model. NeuroToxicology, 2020, 79, 84-94.	3.0	23
49	Cholesterol Modulates Vascular Reactivity to Endothelin-1 by Stimulating a Pro-inflammatory Pathway. Biochemical and Biophysical Research Communications, 2000, 274, 553-558.	2.1	22
50	Increased TNFÎ± production and Cox-2 activity in organotypic brain slice cultures from APPsw transgenic mice. Neuroscience Letters, 2003, 353, 66-68.	2.1	22
51	Chronic cerebrovascular abnormalities in a mouse model of repetitive mild traumatic brain injury. Brain Injury, 2016, 30, 1414-1427.	1.2	22
52	CD40 promotion of amyloid beta production occurs via the NF-Î°B pathway. European Journal of Neuroscience, 2007, 25, 1685-1695.	2.6	19
53	Serum AÎ² Levels as Predictors of Conversion to Mild Cognitive Impairment/Alzheimer Disease in an ADAPT Subcohort. Molecular Medicine, 2009, 15, 432-437.	4.4	19
54	Model of Alzheimerâ€™s disease amyloid-Î² peptide based on a RNA binding protein. Biochemical and Biophysical Research Communications, 2005, 332, 585-592.	2.1	17

#	Article	IF	Citations
55	Serum Î²-Amyloid Correlates with Neuropsychological Impairment. Aging, Neuropsychology, and Cognition, 2009, 16, 203-218.	1.3	17
56	The granulocyte macrophage colony stimulating factor (GM-CSF) regulates amyloid Î² (AÎ²) production. Cytokine, 2008, 42, 336-344.	3.2	16
57	High Serum AÎ² and Vascular Risk Factors in First-Degree Relatives of Alzheimerâ€™s Disease Patients. Molecular Medicine, 2009, 15, 95-100.	4.4	16
58	Potent anti-angiogenic motifs within the Alzheimer Î²-amyloid peptide. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 5-19.	3.0	15
59	Treatment With Nilvadipine Mitigates Inflammatory Pathology and Improves Spatial Memory in Aged hTau Mice After Repetitive Mild TBI. Frontiers in Aging Neuroscience, 2018, 10, 292.	3.4	14
60	The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial. Frontiers in Neurology, 2020, 11, 149.	2.4	14
61	Apolipoprotein E isoforms differentially regulate matrix metallopeptidase 9 function in Alzheimerâ€™s disease. Neurobiology of Aging, 2020, 95, 56-68.	3.1	13
62	Mural cell dysfunction leads to altered cerebrovascular tau uptake following repetitive head trauma. Neurobiology of Disease, 2021, 150, 105237.	4.4	12
63	Nilvadipine suppresses inflammation via inhibition of P-SYK and restores spatial memory deficits in a mouse model of repetitive mild TBI. Acta Neuropathologica Communications, 2020, 8, 166.	5.2	11
64	Blood Pressure Lowering With Nilvadipine in Patients With Mildâ€toâ€Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. Journal of the American Heart Association, 2019, 8, e011938.	3.7	10
65	Epitope-Dependent Effects of Beta-Amyloid Antibodies on Beta-Amyloid Clearance in an In Vitro Model of the Blood-Brain Barrier. Microcirculation, 2011, 18, 373-379.	1.8	9
66	A 3-month-delayed treatment with anatabine improves chronic outcomes in two different models of repetitive mild traumatic brain injury in hTau mice. Scientific Reports, 2021, 11, 7900.	3.3	6
67	A 3D-QSAR model based screen for dihydropyridine-like compound library to identify inhibitors of amyloid beta (AÎ²) production. Bioinformation, 2010, 5, 122-127.	0.5	6
68	Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimerâ€™s AÎ² Peptide. International Journal of Peptide Research and Therapeutics, 2010, 16, 23-30.	1.9	5
69	A fast, miniaturised in-vitro assay developed for quantification of lipase enzyme activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 1474-1480.	5.2	5
70	Alzheimers disease is not associated with the hypertension genetic risk factors PLA2 or G protein ?3, either independently or interactively with apolipoprotein e. American Journal of Medical Genetics Part A, 1999, 88, 465-468.	2.4	4
71	Anatabine Attenuates Tau Phosphorylation and Oligomerization in P301S Tau Transgenic Mice. Brain Disorders & Therapy, 2014, 03, .	0.1	4
72	Novel, natural allosteric inhibitors and enhancers of Candida rugosa lipase activity. Bioorganic Chemistry, 2021, 109, 104732.	4.1	3

#	Article	IF	Citations
73	Neuronal Spleen tyrosine kinase (SYK) mediates cytokine release in Transgenic Tau P301S mice organotypic brain slice cultures. Neuroscience Letters, 2020, 729, 134992.	2.1	2
74	Characterization of immune profile in an aging multiple sclerosis clinic population. Multiple Sclerosis and Related Disorders, 2022, 63, 103818.	2.0	1